



Media Contact
Colleen Kilkenny
AlloSource
720. 382. 2756
ckilkenny@allosource.org

ALLOSOURCE® ANNOUNCES POSITIVE CLINICAL RESULTS FOR ALLOTRUE™-CLEANSED AND LOW-DOSE IRRADIATED TENDONS USED IN KAISER PERMANENTE STUDY OF ACL REVISION RISKS

Centennial, Colo. — March 25, 2015 — [AlloSource®](#), one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced that its tendons processed using its proprietary AlloTrue™ cleansing process, as well as low-dose irradiation, are effective when used in anterior cruciate ligament reconstruction (ACLR). The positive clinical results of the AlloSource tendons used in Kaiser Permanente’s ACL Revision Risks study were presented today at the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting in Las Vegas.

Kaiser Permanente’s retrospective study and associated paper titled *Revision Risk After Allograft Anterior Cruciate Ligament Reconstruction: Graft and Patient Associations* is the largest known study of its kind. The study was conducted on 5,968 primary ACLR cases, using allografts processed with varied techniques such as irradiation doses, AlloWash, AlloTrue and BioCleanse. The median age of the patients at the time of surgery was 34.1-years-old and 61.8 percent of the patients were male.

The study results found BioCleanse graft processing, younger patient age, BPTB allografts and irradiation over 1.8 Mrad were all associated with a higher risk of clinical failure and subsequent revision surgery. AlloSource tendons are treated with irradiation doses between .95-1.4 Mrad. Also, the use of AlloTrue did not significantly affect revision rate.

“Large scale studies like this are important to the medical community,” said Kimberly French, AlloSource Director of Marketing. “Tissue banks use different processes to ensure the safety and quality of their tissue and these results are an example of the success AlloSource has had with AlloTrue.”

AlloSource’s AlloTrue™ technology is a unique, patented process designed to penetrate deep within donor tissue to remove blood and lipids and reduce bioburden. Created through a collaboration of AlloSource’s engineering, research and development, and operations departments, AlloTrue utilizes a combination of antibiotic treatments, alcohol, peroxide (cut tissue only) and multiple water rinses. The deep penetrating cleansing, with minimal tissue manipulation, results in microbial inactivation.

###

About AlloSource

AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource’s products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world’s largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country’s most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website, allograftpossibilities.org.